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I n t r o d u c t i o n
Intraoperative arrhythmias are a concern during anesthesia, and 
selection of anesthetic technique should emphasize the use of drugs 
that minimize the occurrence of potentially fatal ventricular arrhyth-
mias. Although retrospective studies in the veterinary literature are 
lacking, perioperative arrhythmias were reported to occur in 20% to 
50% of human patients (1). The arrhythmogenic potential of anes-
thetic drugs has been assessed on the basis of the arrhythmogenic 
dose of epinephrine (ADE) model, where epinephrine is adminis-
tered at progressively increasing infusion rates until a pre-defined 
ventricular arrhythmia criterion is met (2,3). Comparison between 
anesthetics regarding their arrhythmogenicity (capacity to predis-
pose to ventricular arrhythmias) is then performed by comparison 
between ADE values. A drug or anesthetic regimen is considered 
more arrhythmogenic if ADE decreases in comparison to a control 
and vice-versa (3). The phenothiazine derivatives (acepromazine) and 
butyrophenones (droperidol) are recognized as anti-arrhythmogenic 
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A b s t r a c t
Opioids may exert a protective effect against ventricular arrhythmias via a vagally mediated mechanism. This study evaluated 
the effects of the opioid remifentanil on arrhythmogenicity of epinephrine during halothane anesthesia. Eight dogs were 
assigned to 2 treatments in a randomized crossover design, with 1-week intervals between treatments. Anesthesia was 
maintained with 1.3% end-tidal halothane in oxygen and mechanical ventilation to maintain eucapnia. A constant rate infusion 
of remifentanil (0.72 mg/kg/min) was administered throughout the study in the experimental treatment, while control animals 
received physiologic saline as placebo. The arrhythmogenic dose of epinephrine (ADE), defined as 4 premature ventricular 
complexes (PVCs) within 15 s, was determined by administering progressively increasing infusion rates of epinephrine 
(2.5, 5.0, and 10 mg/kg/min), allowing 20 min intervals between each infusion rate. In both treatments, epinephrine infusions 
induced bradyarrhythmias and atrioventricular conduction disturbances, which were followed by escape beats and PVCs. In 
the remifentanil treatment, mean 6 s ADE values (11.3 6 4.9 mg/kg) did not differ from values observed in control animals 
(9.9 6 6.1 mg/kg). On the basis of the ADE model for assessing the arrhythmogenity of drugs during halothane anesthesia, the 
present study did not demonstrate a protective effect of remifentanil (0.72 mg/kg/min) against ventricular arrhythmias in dogs.
Résumé
Les opioïdes peuvent avoir un effet protecteur contre les arythmies ventriculaires via un mécanisme à médiation vagale. La présente étude visait 
à évaluer les effets de l’opioïde remifentanil sur l’effet arythmogénique de l’adrénaline durant une anesthésie à l’halothane. Huit chiens ont été 
assignés à 2 traitements selon un design expérimental croisé avec répartition au hasard, avec un intervalle de 1 semaine entre les traitements. 
L’anesthésie a été maintenue avec une concentration télo-expiratoire de 1,3 % d’halothane dans de l’oxygène et ventilation mécanique afin de 
maintenir l’eucapnée. Un taux constant d’infusion de remifentanil (0,72 mg/kg/min) a été administré tout au long de l’étude pour le groupe 
avec traitement expérimental, alors que les animaux témoins recevaient de la saline physiologique à titre de placebo. La dose d’adrénaline 
ayant un effet arythmogénique (ADE), définie comme étant celle causant 4 complexes ventriculaires prématurés (PVCs) en moins de 15 s, 
a été déterminée en administrant de manière progressive des taux croissants d’adrénaline en infusion (2,5, 5,0 et 10 mg/kg/min), avec des 
intervalles de 20 min entre chaque taux d’infusion. Lors des deux traitements, les infusions d’adrénaline ont induit de la brady-arythmie 
et des interférences dans la conduction atrio-ventriculaire, qui ont été suivies par des battements échappés et des PVCs. Lors du traitement 
avec le remifentanil, les valeurs moyennes 6 s d’ADE (11,3 6 4,9 mg/kg) ne différaient pas des valeurs observées pour les animaux témoins 
(9,9 6 6,1 mg/kg). Basé sur le modèle de l’ADE pour évaluer l’effet arythmogène de drogues durant une anesthésie à l’halothane, la présente 
étude n’a pas permis de démontrer un effet protecteur pour le remifentanil (0,72 mg/kg,min) contre l’arythmie ventriculaire chez les chiens.
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agents since previous administration of these drugs cause an increase 
in the dose of epinephrine necessary to induce ventricular premature 
depolarizations (VPCs) (4,5).
Opioids are widely used in balanced anesthesia techniques. In 
conscious and in anesthetized dogs, the opioid morphine decreases 
the risk of ventricular fibrillation, which is a terminal event that may 
follow VPCs (6,7). Evidence for an anti-arrhythmogenic effect of 
morphine in these previous studies was provided by the repetitive 
extrasystole threshold method (6–8). In this methodology, repetitive 
extrasystoles (VPCs) are induced by a constant current stimulator 
implanted in the right ventricle, and an increase in the amount of 
electrical current necessary to induce repetitive extrasystoles in com-
parison to a control provides evidence for an anti-arrhythmogenic 
effect (8). The short acting opioid fentanyl (30 mg/kg) protected 
the heart against ventricular fibrillation in dogs anesthetized with 
alpha-chloralose as shown by increased amount of electrical current 
applied to the right ventricle that induced ventricular fibrillation (9). 
In conscious rats, morphine administration increased the amount of 
epinephrine necessary to induce VPCs and cardiac arrest, apparently 
via a mechanism dependent on the action of the opioid on brain mu 
receptors (10). 
In spite of evidence showing that opioids may protect the heart 
against ventricular arrhythmias, to our knowledge, there are no 
published studies using the ADE methodology for assessing anti-
arrhythmogenic potential of the opioid remifentanil in halothane 
anesthetized dogs. The mu opioid agonist remifentanil approaches 
the ideal profile of an injectable agent suitable for a continuous infu-
sion regimen (11). This opioid has a very rapid onset and offset of 
action as metabolism occurs via nonspecific esterases (11). In man 
and in dogs remifentanil results in fast recoveries and relatively 
stable plasma levels during maintenance of a constant rate infusion 
(11,12). We hypothesized that remifentanil exerts a protective effect 
against epinephrine induced ventricular premature depolarizations 
during halothane anesthesia. 
M a t e r i a l s  a n d  m e t h o d s
Animals and study design
This study was approved by the Institutional Animal Care 
Committee (protocol 138-06 CEEA). Eight healthy spayed adult 
female dogs (weight 15.4 6 2.3 kg) were used in a randomized 
crossover design. Each dog received 2 treatments (control and 
remifentanil) with a minimum of 1-wk interval between experiments. 
Health status was based on physical examination, complete blood 
(cell) count, electrocardiography, and blood gas analysis.
Experimental protocol
Anesthesia was induced with 5% halothane (Halotano; Cristália, 
Itapira, SP, Brazil) in oxygen delivered by a facemask attached to a 
circle breathing system (Conquest 3000; HB Hospitalar, São Paulo, SP, 
Brazil). After endotracheal tube placement, vaporizer settings were 
adjusted to maintain end-tidal halothane concentrations at 1.3% in 
both treatments. An infrared gas analyzer (Gas analyzer module 
G-AO; Datex-Ëngstrom, Helsinki, Finland) calibrated with a stan-
dard gas mixture containing 5% carbon dioxide (CO2), 55% oxygen 
(O2), 33% nitrous oxide (N2O), and 3% anesthetic agent (Quick Cal 
Calibration Gas; Datex-Ëngstrom, Helsinki, Finland) was connected 
to the distal end of the endotracheal tube to allow continuous moni-
toring of end-tidal halothane concentrations. Inspiratory positive 
pressure ventilation (Conquest 3000, HB Hospitalar) was employed 
throughout the study (peak inspiratory pressure of 8 to 15 cm H2O, 
inspiration-to-expiration ratio of 1:2, and respiratory rate between 
8 to 18 breaths/min) aiming to maintain arterial CO2 tension (PaCO2) 
between 35 and 40 mm Hg. To ensure that PaCO2 values were within 
the reference ranges, arterial blood gases were measured (pH/Blood 
Gas Analyzer Model 348; Chiron Diagnostics, Halstead, UK) at least 
2 times between epinephrine infusions for ADE determination; 
ventilatory parameters were further adjusted in order to achieve the 
desired PaCO2 range as needed. Throughout the study, esophageal 
temperature was maintained between 37.0 and 38.58C by means 
of a forced warm air blanket (Warmtouch; Mallinkrodt Medical, 
Pleasanton, California, USA). 
A 20-gauge catheter (Insyte; Becton-Dickinson, Sandy, Utah, USA) 
was placed in the cephalic vein for drug administration and for fluid 
therapy with Lactated Ringer’s solution administered at 5 mL/kg/h 
by means of an infusion pump (LF 2001; Lifemed, São Paulo, SP, 
Brazil). Adhesive electrodes were placed on the skin to monitor 
lead II electrocardiogram (ECG), while systolic, diastolic, and mean 
arterial pressure (SAP, DAP and MAP) values where monitored via 
a fluid-filled pressure transducer (model PX260; Baxter Healthcare 
Corp, Irving, California, USA) connected to an 18-gauge catheter 
(Insyte; Becton-Dickinson) placed in the femoral artery. Accuracy 
of the pressure transducer was previously checked with a mercury 
column prior to each experiment.
In the control treatment, anesthesia was maintained with halothane 
and a constant rate infusion of physiologic saline (placebo), whereas 
in the experimental treatment anesthesia was maintained with 
halothane and a constant rate infusion of remifentanil (0.72 mg/kg/
min). Infusion treatments were administered by means of a syringe 
pump (ST 680; Samtronic, São Paulo, SP, Brazil). The same end-
tidal halothane concentration (1.3%) was used in both treatments; 
also, the infusion rates (mL/kg/min) administered intravenously 
(physiologic saline or remifentanil) were the same regardless of the 
treatment group. 
A period of 60 min of constant end-tidal halothane (1.3%) 
was allowed prior to determining ADE values. Epinephrine was 
administered at progressively higher infusion rates (2.5, 5.0, and 
10.0 mg/kg/min) by means of a peristaltic infusion pump (LF 
2001; Lifemed, São Paulo, SP, Brazil), until achieving a pre-defined 
arrhythmia criterion (13). Each infusion rate was maintained for 
3 min, with 20-min intervals between infusions. When the ventricular 
arrhythmia criterion was observed on the ECG tracing, epineph-
rine infusion was immediately interrupted and a lidocaine bolus 
(2 mg/kg, IV) was administered to prevent arrhythmia progression 
to ventricular fibrillation.
Since prolonged epinephrine administration may cause an increase 
in base deficit due to vasoconstriction leading to impaired peripheral 
perfusion, eventual reductions in bicarbonate levels , 19 mEq/L 
were treated by administering IV boluses of sodium bicarbonate 
(0.2 mEq/kg) until arterial bicarbonate levels were within reference 
ranges (19 to 24 mEq/L). 
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The ADE criterion was considered fulfilled after observing at 
least 4 VPCs within a 15-s period during epinephrine infusion 
or until 1 min after the end of the infusion. The ECG tracing was 
printed throughout the procedure for further analysis. The ADE 
values (mg/kg) where calculated as the time when the first VPC of 
the series that met the ADE criterion (min) times the infusion rate 
(mg/kg/min).
Heart rate (HR), SAP, DAP, MAP were recorded prior to starting the 
infusion rate where the ADE criterion was observed (baseline) and at 
the time of ADE observation.
At the end of the procedure, the inhalant anesthetic and infusion 
drugs were discontinued and the dogs were allowed to recover 
from anesthesia.
Statistical analysis
Data are expressed as mean 6 s. Mean ADE values and blood gas 
values recorded prior to starting the epinephrine infusion rate that 
resulted in the ventricular arrhythmia criterion were compared by 
means of a paired t-test. A two-way analysis of variance (ANOVA) 
followed by a Bonferroni-adjusted Student’s t-test was used for 
comparison of cardiovascular variables obtained between treatments, 
whereas a paired t-test was used to compare cardiovascular data 
obtained within each group. Differences were considered significant 
when P , 0.05. 
R e s u l t s
There was no significant difference between treatments for pH, 
PaCO2 and PaO2 values prior to starting the epinephrine infusion 
that resulted in ventricular arrhythmias (overall mean 6 s values: 
7.36 6 0.02, 36 6 2 mm Hg, and 509 6 33 mm Hg for pH, PaCO2, 
and PaO2, respectively). Arterial bicarbonate was significantly lower 
in the remifentanil treatment (20.0 6 0.7 mEq/L) compared with the 
controls (21.2 6 1.3 mEq/L). 
Cardiovascular variables recorded at baseline and at the time 
of ADE observation are reported in Table I. Heart rate (HR), MAP, 
and DAP were significantly lower in the remifentanil treatment at 
baseline. In the control treatment, HR decreased in comparison with 
the baseline at the time of ventricular arrhythmia formation. In both 
treatments SAP, DAP, and MAP increased from baseline at the time 
of ADE observation.
Overall incidence of supraventricular and ventricular arrhythmias 
was similar between groups (Table II). Bradycardia (HR , 60 beats/
min), sinus arrest, and conduction disturbances (1st and 2nd degree 
atrioventricular heart blocks) were observed at the beginning 
of epinephrine infusion in both groups. With the progression of 
epinephrine infusion, ventricular escape beats and idioventricular 
rhythm became evident. The arrhythmia criterion was later achieved 
by observing VPCs, bigeminism, trigeminism, and ventricular 
tachycardia. No animals progressed to ventricular fibrillation after 
achieving the ventricular arrhythmia criterion.
Mean ADE values in the remifentanil treatment (11.3 6 4.9 mg/kg) 
did not differ from mean ADE values observed in the control treat-
ment (9.1 6 6.1 mg/kg).
D i s c u s s i o n
In this study, remifentanil resulted in lower HR, MAP, and DAP 
values prior to the epinephrine infusion that fulfilled the ventricular 
arrhythmia criterion. Vagally mediated bradycardia is a common 
feature of opioid agents and may result in reduction in arterial 
blood pressure during anesthesia (11). Remifentanil was also associ-
ated with a statistically significant reduction in bicarbonate levels. 
However, the clinical relevance of the phenomenon appears to be 
Table I. Cardiovascular variables observed before starting the 
infusion rate where the ADE criterion was met (baseline) and 
immediately prior to the moment where the first VPC that met 
ADE criterion (ADE) was observed in 8 halothane anesthetized 
dogs receiving a constant rate infusion of physiologic saline 
(control) or remifentanil (0.72 mg/kg/min)
  Baseline ADE 
HR (beats/min) Control 81 6 12 49 6 10a
 Remifentanil 74 6 15b 61 6 18
   
SAP (mm Hg) Control 126 6 21 283 6 12a
 Remifentanil 107 6 11 274 6 23a
   
DAP (mm Hg) Control 73 6 17 164 6 12a
 Remifentanil 52 6 10b 169 6 12a
   
MAP (mm Hg) Control 88 6 18 196 6 8a
 Remifentanil 67 6 11b 194 6 15a
Values are presented as mean 6 s.
a Significant difference from baseline (P , 0.05).
b Significant difference from Control treatment (P , 0.05).
Table II. Incidence (number of animals) of ventricular and 
supraventricular de arrhythmias observed during the 
epinephrine infusion where the ADE criterion was observed in 
8 halothane anesthetized dogs receiving a constant rate 
infusion of physiologic saline (control) or remifentanil 
(0.72 mg/kg/min)
Rhythm   Control Remifentanil
Bradycardia (HR , 60 bpm) 6 7
Sinus arrhythmia  6 4
Second degree AV block 4 3
Sinus arrest  3 1
 Accelerated idioventricular rhythm 2 2
AV dissociation  6 5
Atrial premature complexes 1 —
Ventricular escape beats 5 7
Ventricular escape rhythm 6 6
Ventricular premature complexes 6 6
Bigeminism  1 2
Trigeminism  2 —
Ventricular tachycardia 7 7
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insignificant, since mean bicarbonate values were within reference 
ranges (19 to 24 mEq/L) in both treatments, and the difference 
between mean values was small.
In dogs, a remifentanil infusion rate similar to that used in the 
present study (0.72 mg/kg/min) was estimated to reduce enflurane 
minimum alveolar concentration (MAC) by approximately 50% (13). 
Opioid agents reduce the MAC of inhalant anesthetics and this 
anesthetic sparing effect may result in an overall improvement in 
hemodynamic function, providing that opioid-induced bradycardia 
is reversed by an anticholinergic agent (14). In our study, the same 
end-tidal halothane concentrations were used in both remifentanil 
and control treatments. Although one may expect that use of MAC 
corrected end-tidal anesthetic concentrations could have influenced 
some of the cardiovascular parameters assessed in the present study 
(for example, blood pressure), it is not known whether the use of 
equipotent halothane concentrations could bear an impact on the 
ADE values recorded in both treatments.
Bradycardia, periods of sinus arrest, and conduction disturbances 
(1st and 2nd degree AV blocks, atrioventricular dissociation) were 
coincident with increased arterial blood pressure in both treatments 
during epinephrine administration, suggesting that vagal tone was 
increased due to baroreceptor stimulation. With the progression of 
the catecholamine infusion, ventricular escape beats preceded the 
VPCs that were present in the form of isolated VPCs, bigeminy, 
trigeminy, and multiform ventricular tachycardia. In our study, 
ADE was considered to be achieved after the observation of at least 
4 VPCs within a 15-s period (5,15). A broader ADE criterion, defined 
as the observation of at least 4 ectopic ventricular contractions 
(EVCs), has been reported in the literature (16–19). Although VPCs 
and ventricular escape beats originate through different mechanisms, 
both phenomena may be considered as EVCs (19). In the present 
study, a more specific criterion (VPCs) was used as the end point 
for ADE determination because a broader criterion (EVCs instead 
of VPCs) does not allow direct comparison between ADE values 
observed for different treatments (19).
Based on the ADE method for studying the arrhythmogenicity 
of drugs during halothane anesthesia, it appears that remifentanil 
does not have an anti-arrhythmogenic action. However, one should 
consider that the previous reports showing evidence for an anti-
arrhythmogenic effect of other opioids in canine species were per-
formed using different methods for inducing ventricular arrhythmias 
(6–7). In some of these studies, dogs were either conscious or anes-
thetized with alpha-chloralose and the anti-arrhythmogemic effect 
of the opioid morphine was evidenced by an increase in the current 
threshold necessary to induce VPCs, rather than by an increase in 
ADE values (6–7). The ventricular fibrillation threshold, measured 
as the amount of current delivered by a catheter implanted in the 
right ventricle that induced ventricular fibrillation, was increased by 
29% with the use of the mu opioid agonist fentanyl (30 mg/kg, IV) 
in alpha-chloralose anesthetized dogs after experimentally induced 
hemorrhage (9). The action of morphine against ventricular arrhyth-
mias in alpha-chloralose anesthetized dogs was apparently medi-
ated via opioid induced changes in vagal tone, since vagotomy or 
atropine administration abolished the protective effect of the opioid 
against ventricular arrhythmias (6). However, the hypothesis that 
the anti-arrhythmogenic effect of mu opioid agonists involves 
an increase in efferent vagal tone may not apply to all drugs of 
this class. In dogs anesthetized with alpha-chloralose, muscarinic 
blockade with atropine did not affect the anti-fibrillatory effect of 
fentanyl, suggesting that the contribution of vagal efferent activ-
ity for the anti-arrhythmogenic effect may vary among mu opioid 
agonists (9). It appears that the anti-fibrillatory effect of fentanyl in 
dogs involves both a vagal component (baroreflex) and a decrease 
in sympathetic tone (9).
We used the model of ADE determination during halothane anes-
thesia because this is a widely used method for accessing the pro- or 
anti-arrhythmogenic effects of drugs used during the perianesthetic 
period (2–5, 15). If 1 drug is to be tested for its anti-arrhythmogenic 
potential during anesthesia, halothane would be an adequate agent 
to be used in the experimental model since this drug is known for 
sensitizing the myocardium to the arrhythmogenic action of cath-
ecolamines (2). However, halothane was shown to reduce parasym-
pathetic and sympathetic efferent activity in a dose related fashion 
(20). Since the anti-arrhythmogenic effects of opioids appears to take 
place via changes in autonomic balance (6), the inhibitory effect of 
halothane on autonomic efferent activity may have represented a 
confounding factor. 
In halothane anesthetized dogs, an increase in vagal activity 
induced by direct electrical stimulation of both vagi increased the 
dose of epinephrine necessary to induce ventricular fibrillation (21). 
However, in the same experimental model, morphine premedication 
(1 mg/kg) did not increase the arrhythmogenic threshold of epi-
nephrine (21). It appears that alpha-chloralose anesthesia does not 
interfere with the protective effect of opioids against epinephrine-
induced ventricular arrhythmias, as morphine (0.1 mg/kg) raised 
the dose of epinephrine necessary to induce VPCs in a model of ADE 
determination in alpha-chloralose anesthetized rats (10). Based on 
these evidences, one may hypothesize that the ADE model used in 
the present study could have shown an anti-arrhythmogenic effect 
of remifentanil during alpha-chloralose anesthesia.
In previous studies, the anti-arrhythmogenic effect of the opioid 
morphine was shown either in conscious dogs or in dogs anesthe-
tized with alpha-chloralose, a hypnotic agent drug that apparently 
causes minimal interference in autonomic activity (6,7). In spite of 
the advantages of alpha-chloralose with respect to cardiovascular 
stability and lack of significant interference in autonomic balance, 
this hypnotic agent may result in excessively prolonged recoveries 
from anesthesia and this drug has been recommended as an anes-
thetic agent suitable only for non-recovery studies in dogs and other 
laboratory animals (22,23). Otherwise, the volatile agent isoflurane 
is proven as an adequate drug for maintaining clinical anesthesia 
in dogs, providing fast and uncomplicated recoveries. Although 
isoflurane is highly suitable for clinical anesthesia, this agent does 
not sensitize the myocardium to epinephrine induced arrhythmias 
and is not the ideal anesthetic in an ADE model for assessing the 
pro- or anti-arrhythmic effects of drugs. 
In summary, the opioid remifentanil did not influence epinephrine-
 induced ventricular arrhythmias in halothane anesthetized dogs. 
Although the use of opioids such as remifentanil during inhalant 
anesthesia offers advantages such as reduction in inhalant anesthetic 
requirements (13), it apparently does not minimize the arrhyth-
mogenic action of epinephrine during halothane anesthesia.
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